Navigation Links
Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
Date:5/19/2009

DOYLESTOWN, Pa., May 19 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), www.quigleyco.com, today announced that it has uncovered an improper financial relationship between Ted Karkus and the Company's Quigley Pharma, Inc. wholly-owned subsidiary COO, Dr. Richard A. Rosenbloom. The Company has come into possession of documentary evidence of undisclosed payments from Karkus to Rosenbloom continuing at least since 2008.

The Company is investigating as to whether any material non-public information was communicated from Rosenbloom to Karkus.

In April of 2008, Karkus solicited Charles Phillips, COO of The Quigley Corporation since 1989, to join him and others in a proxy fight to unseat the Management and Board of The Quigley Corporation. Phillips rejected the Karkus proposal. Shortly after this rejection, Karkus entered into a financial arrangement with Rosenbloom.

In a case brought by the Company in the Eastern District Court of Pennsylvania against Karkus and his slate of proposed directors, Karkus answered under oath "no" in his deposition when asked if he had any financial or other arrangements with any member of The Quigley Corporation's staff.

All employees of The Quigley Corporation received a notice in May of 2008 requiring that any contact with any shareholder be communicated to Management and memorialized. On April 13, 2009 the Company sent the same notice to all employees asking for written responses. Dr. Rosenbloom stated that he had no contact with any shareholder and, in particular, had no contact with Ted Karkus.

Guy J. Quigley, Chairman, President and Chief Executive Officer of The Quigley Corporation, stated, "On two separate occasions I contacted the entire staff of The Quigley Corporation asking for written confirmation of any contact with Karkus and his proxy group. Dr. Richard Rosenbloom denied any contact with Karkus. This matter has been forwarded to the Audit Committee and the Company's auditors, Amper, Politziner & Mattia, for investigation and review. The Company is also reviewing its duties to notify the United States Attorney and the District Attorney of Bucks County of these actions."

Richard Rosenbloom has been suspended from duty pending further investigations and the Company has appointed Michael Petteruti as COO of the Pharma division. Since joining Quigley, Petteruti has established and administered over $10M in capital, operating, R&D, and project budgets; authored and implemented strategic business development and market research plans; developed and communicated short-term and long-range goals throughout the organization; negotiated and managed development agreements with service providers and experts on key product and drug candidates such as QR-333, QR-448, QR-336; and also oversees the Company's patent portfolio.

Mr. Petteruti is spearheading business development efforts which have translated into the licensing of the Quigley Pharma scar patent QR-340 and has recently opened discussions with a number of potential collaborators / licensees for other Pharma drug and product candidates.

Mr. Petteruti is responsible for the consolidation and closure of the smaller Quigley Manufacturing Elizabethtown facility and the implementation of a contract manufacturing business development plan for the Company's Lebanon OTC facility.

Prior to joining The Quigley Corporation, Mr. Petteruti held various executive positions with the AM Todd Company as Vice President of New Business Development, Vice President Technical Services as well as Vice President of Operations and Technical Services and Vice President of Sales and Marketing for a Todd subsidiary. The AM Todd Company & Group is a seller of natural products, botanicals, food and flavor ingredients with international operations.

Mr. Petteruti has degrees in both microbiology and chemistry.

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

Important Additional Information

The Quigley Corporation ("Quigley" or the "Company") filed a definitive proxy statement with the Securities and Exchange Commission (the "SEC") on April 2, 2009 in connection with the 2009 Annual Meeting of Stockholders and began the process of mailing the definitive proxy statement and a WHITE proxy card to stockholders. The Company's stockholders are strongly advised to read Quigley's proxy statement as it contains important information. Stockholders may obtain an additional copy of Quigley's definitive proxy statement and any other documents filed by the Company with the SEC for free at the SEC's website at http://www.sec.gov. Copies of the definitive proxy statement are available for free at http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=07814.

In addition, copies of the Company's proxy materials may be requested at no charge by contacting MacKenzie Partners, Inc. at 1-800-322-2885 or via email at quigley@mackenziepartners.com. Detailed information regarding the names, affiliations and interests of individuals who are participants in the solicitation of proxies of Quigley's stockholders is available in Quigley's definitive proxy statement filed with SEC on April 2, 2009.

    CONTACT:

    Gerard M. Gleeson
    The Quigley Corporation
    Vice President, CFO
    (215) 345-0919

    Media
    Mark Harnett / Bob Marese
    MacKenzie Partners, Inc.
    212-929-5500
    quigley@mackenziepartners.com

    Investor Relations
    Carl Hymans
    G. S. Schwartz & Co.
    212-725-4500
    carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
2. Conseco Responds to RiskMetrics Groups Recommendation on Dissident Director Nominee
3. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
4. LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees
5. RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
6. Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
7. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
8. Smart Balance, Inc. to Hold Annual Meeting of Stockholders on May 20, 2009
9. Apex Bioventures Acquisition Corp. Sets Date for Special Meeting of Stockholders to Approve Dissolution
10. CPC Corrects Time of Conference Call for Annual Meeting of Stockholders
11. AMERIGROUP Corporation to Webcast Annual Meeting of Stockholders on May 7, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million ... million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will ... Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration of ...
(Date:5/26/2016)... , ... May 26, 2016 , ... In an effort to provide hair restoration information ... both Snapchat users and those who do not use the app. Dr. Mohebi, the founder ... page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response to ...
(Date:5/26/2016)... ... May 26, 2016 , ... North Cypress Medical ... at Blackhorse Golf Club in Cypress. With the help of community partners, the event ... empowers, and renews hope for wounded service members and their families through health, wellness, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a leading developer ... Instructor Certification Course in Stoughton, Massachusetts. The course was led by Power Systems’ ... 8 hour interactive course to qualify participants as certified PowerWave trainers. , ...
(Date:5/26/2016)... ... ... The introduction of our professional athletes coincides with the company’s new campaign: “LOOK ... are proud to introduce Meghan Klingenberg, defender and World Champion with the US Women’s ... Los Angeles who was a second round selection in the 2012 NFL draft. We ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Open Access Journal Focusing on ... Elsevier , a world-leading provider of scientific, technical ... launch of Clinical Neurophysiology Practice ... clinical practice issues in clinical neurophysiology. The journal will ... and didactic reviews. It is an official journal of ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
(Date:5/23/2016)... ALBANY, New York , May 23, 2016 /PRNewswire/ ... new market report titled, " Exocrine Pancreatic Insufficiency Market ... Forecast 2013 - 2023 ." According to the report, ... at a CAGR of 8.3% from 2015 to 2023 ... pancreatic insufficiency (EPI) is a condition characterized by the ...
Breaking Medicine Technology: